Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 40 to 85 years; of either sex~* Primary femorotibial osteoarthritis according to American College of Rheumatology (ACR) clinical and radiographic criteria , and meeting protocol-specified X-ray criteria in the target knee at screening~* Pain score in the target knee and/or the need for regular symptomatic treatment of knee pain with paracetamol (acetaminophen), systemic non-steroidal anti-inflammatory drugs (NSAIDs) including cyclooxygenase (COX)-2 selective inhibitors (coxibs), or tramadol on most days in the previous month (that is, more than half of the days in the previous month)~* A history of pain due to Osteoarthritis in the target knee for at least 6 months~* A protocol-specified pain score for the target knee in response to Question 1 of the WOMAC pain index (how much pain have you had \[in the target knee, over the past 48 hours\] when walking on a flat surface?) after washout of at least 5 half-lives of analgesic medication(s): acetaminophen, topical or oral NSAIDS, coxibs, opioids, and/or tramadol~* Women of childbearing potential must use a form of contraception with a failure rate of less than 1 percent per year throughout the trial~Exclusion Criteria:~* Malalignment of greater than 5 degrees in the femorotibial axis of the target knee~* Clinical signs of inflammation (redness) in the target knee~* Intra-articular administration of corticosteroids or hyaluronic acid into either knee within 6 months before Screening~* Planned knee surgery (affecting either the target or the contralateral knee) within the next two years~* Concomitant conditions or treatments deemed to be incompatible with trial participation~* Any contraindication to MRI according to MRI guidelines, including the inability to undergo a knee MRI exam because of inability to fit in the scanner or knee coil~* Pregnancy or breastfeeding~* Participation in another clinical trial within the 30 days (or 5 half-lives of the investigated compound, whichever is longer) before screening~* Legal incapacity or limited legal capacity

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
- Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles (Type: EXPERIMENTAL): Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
- Sprifermin (AS902330) 30 mcg- 4 Cycles (Type: EXPERIMENTAL): Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
- Sprifermin (AS902330) 100 mcg/Placebo (2 cycles) (Type: EXPERIMENTAL): Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
- Sprifermin (AS902330) 100 mcg- 4 Cycles (Type: PLACEBO_COMPARATOR): Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).